NASDAQ

SCYNEXIS, Inc. (SCYX)

542 Thanks from members

SCYNEXIS, Inc. (SCYX) displays a polarized yet active market profile, characterized by strong cash runway extensions into 2029 following a private placement, pivotal clinical updates for SCY-770 and SCY-247, and split institutional ratings alongside notable GAAP earnings surprises driven by warrant liability revaluations.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →